



ÅRSREGNSKAPET FOR REGNSKAPSÅRET 2024 - GENERELL INFORMASJON

Enheten

Organisasjonsnummer: 991 729 666
Organisasjonsform: Aksjeselskap
Foretaksnavn: ABBOTT MEDICAL NORWAY AS
Forretningsadresse: Rolfsbuktheien 4C
1364 FORNEBU

Regnskapsår

Årsregnskapets periode: 01.01.2024 - 31.12.2024

Konsern

Morselskap i konsern: Nei

Regnskapsregler

Regler for små foretak benyttet: Nei
Benyttet ved utarbeidelsen av årsregnskapet til selskapet: Regnskapslovens alminnelige regler

Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Fredrik Bjoernulfson
Dato for fastsettelse av årsregnskapet: 30.06.2025

Grunnlag for avgivelse

År 2024: Årsregnskapet er elektronisk innlevert
År 2023: Tall er hentet fra elektronisk innlevert årsregnskap fra 2024

Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.

Brønnøysundregistrene, 05.07.2025



Resultatregnskap

Beløp i: NOK	Note	2024	2023
RESULTATREGNSKAP			
Inntekter			
Salgsinntekt	2	188 539 333	165 882 946
Sum inntekter		188 539 333	165 882 946
Kostnader			
Varekostnad	3	149 590 799	127 944 620
Lønnskostnad	4	20 043 093	19 241 717
Avskrivning på varige driftsmidler og immaterielle eiendeler	5	2 122 722	2 004 782
Annen driftskostnad	3	11 108 591	11 339 980
Sum kostnader		182 865 205	160 531 099
Driftsresultat		5 674 128	5 351 847
Finansinntekter og finanskostnader			
Renteinntekt fra foretak i samme konsern	3,6	285 976	179 094
Annen renteinntekt	6	664 566	369 579
Annen finansinntekt		2 063	28 607
Sum finansinntekter		952 605	577 280
Rentekostnad til foretak i samme konsern	3 , 6	48 748	64 930
Annen rentekostnad	6	15 895	2 159
Annen finanskostnad		35 549	164 047
Sum finanskostnader		100 192	231 136
Netto finans		852 413	346 144
Resultat før skattekostnad		6 526 541	5 697 991
Skattekostnad		1 498 070	1 339 328
Årsresultat		5 028 471	4 358 663
Overføringer og disponeringer			
Overføringer til/fra annen egenkapital		5 028 471	4 358 663
Sum overføringer og disponeringer		5 028 471	4 358 663



Balanse

Beløp i: NOK	Note	2024	2023
BALANSE - EIENDELER			
Anleggsmidler			
Immaterielle eiendeler			
Utsatt skattefordel		1 800 237	1 469 438
Sum immaterielle eiendeler		1 800 237	1 469 438
Varige driftsmidler			
Maskiner og anlegg	5	2 867 883	3 558 876
Driftsløsøre, inventar, verktøy, kontormaskiner og lignende	5	92 634	180 711
Sum varige driftsmidler		2 960 517	3 739 587
Sum anleggsmidler		4 760 754	5 209 025
Omløpsmidler			
Varer			
Varer	3, 8	17 233 831	14 557 412
Sum varer		17 233 831	14 557 412
Fordringer			
Kundefordringer		24 668 445	17 476 505
Andre fordringer	3	12 881 654	5 941 272
Sum fordringer		37 550 099	23 417 777
Bankinnskudd, kontanter og lignende			
Bankinnskudd, kontanter og lignende	9	14 658 597	15 053 160
Sum bankinnskudd, kontanter og lignende		14 658 597	15 053 160
Sum omløpsmidler		69 442 527	53 028 349
SUM EIENDELER		74 203 281	58 237 374

BALANSE - EGENKAPITAL OG GJELD

Egenkapital

Innskutt egenkapital



Balanse

Beløp i: NOK	Note	2024	2023
Selskapskapital	10, 11	200 000	200 000
Sum innskutt egenkapital		200 000	200 000
Opptjent egenkapital			
Annen egenkapital	11	33 994 325	28 965 854
Sum opptjent egenkapital		33 994 325	28 965 854
Sum egenkapital		34 194 325	29 165 854
Sum langsiktig gjeld		0	0
Kortsiktig gjeld			
Leverandørgjeld		581 821	1 375 813
Betalbar skatt	7	1 828 869	1 931 694
Skyldige offentlige avgifter		10 699 686	10 694 314
Kortsiktig konserngjeld	3	21 738 654	9 610 029
Annen kortsiktig gjeld	5	5 159 926	5 459 670
Sum kortsiktig gjeld		40 008 956	29 071 520
Sum gjeld		40 008 956	29 071 520
SUM EGENKAPITAL OG GJELD		74 203 281	58 237 374



Brønnøysundregistrene

ÅRSREGNSKAP FOR REGNSKAPSÅRET 2024 - GENERELL INFORMASJON

Journalnummer: 2025 629137

Enheten

Organisasjonsnummer: 991 729 666
Organisasjonsform: Aksjeselskap
Foretaksnavn: ABBOTT MEDICAL NORWAY AS
Forretningsadresse: Rolfsbuktveien 4C
1364 FORNEBU

Regnskapsår

Årsregnskapets periode: 01.01.2024 - 31.12.2024

Konsern

Morselskap i konsern: Nei

Regnskapsregler

Regler for små foretak benyttet: Nei
Benyttet ved utarbeidelsen av
årsregnskapet til selskapet: Regnskapslovens alminnelige regler

Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Fredrik Bjoernulfson
Dato for fastsettelse av årsregnskapet: 30.06.2025

Grunnlag for avgivelse

År 2024: Årsregnskap er elektronisk innlevert.
År 2023: Tall er hentet fra elektronisk innlevert årsregnskap fra 2024.

Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.

Brønnøysundregistrene, 05.07.2025



Organisasjonsnr: 991 729 666
ABBOTT MEDICAL NORWAY AS

RESULTATREGNSKAP

Beløp i: NOK	Note	2024	2023
RESULTATREGNSKAP			
Inntekter			
Salgsinntekt	2	188 539 333	165 882 946
Sum inntekter		188 539 333	165 882 946
Kostnader			
Varekostnad	3	149 590 799	127 944 620
Lønnskostnad	4	20 043 093	19 241 717
Avskrivning på varige driftsmidler og immaterielle eiendeler	5	2 122 722	2 004 782
Annen driftskostnad	3	11 108 591	11 339 980
Sum kostnader		182 865 205	160 531 099
Driftsresultat		5 674 128	5 351 847
Finansinntekter og finanskostnader			
Renteinntekt fra foretak i samme konsern	3,6	285 976	179 094
Annen renteinntekt	6	664 566	369 579
Annen finansinntekt		2 063	28 607
Sum finansinntekter		952 605	577 280
Rentekostnad til foretak i samme konsern	3,6	48 748	64 930
Annen rentekostnad	6	15 895	2 159
Annen finanskostnad		35 549	164 047
Sum finanskostnader		100 192	231 136
Netto finans		852 413	346 144
Resultat før skattekostnad		6 526 541	5 697 991
Skattekostnad		1 498 070	1 339 328
Årsresultat		5 028 471	4 358 663
Overføringer og disponeringer			
Overføringer til/fra annen egenkapital		5 028 471	4 358 663
Sum overføringer og disponeringer		5 028 471	4 358 663



Organisasjonsnr: 991 729 666
ABBOTT MEDICAL NORWAY AS

BALANSE

Beløp i: NOK Note 2024 2023

BALANSE - EIENDELER

Anleggsmidler

Immaterielle eiendeler

Utsatt skattefordel 1 800 237 1 469 438
Sum immaterielle eiendeler 1 800 237 1 469 438

Varige driftsmidler

Maskiner og anlegg 5 2 867 883 3 558 876
Driftsløsøre, inventar,
verktøy, kontormaskiner
og lignende 5 92 634 180 711
Sum varige driftsmidler 2 960 517 3 739 587

Sum anleggsmidler 4 760 754 5 209 025

Omløpsmidler

Varer

Varer 3, 8 17 233 831 14 557 412
Sum varer 17 233 831 14 557 412

Fordringer

Kundefordringer 24 668 445 17 476 505
Andre fordringer 3 12 881 654 5 941 272
Sum fordringer 37 550 099 23 417 777

Bankinnskudd, kontanter og lignende

Bankinnskudd, kontanter
og lignende 9 14 658 597 15 053 160
Sum bankinnskudd,
kontanter og lignende 14 658 597 15 053 160

Sum omløpsmidler 69 442 527 53 028 349

SUM EIENDELER 74 203 281 58 237 374

BALANSE - EGENKAPITAL OG GJELD

Egenkapital

Innskutt egenkapital

Selskapskapital 10, 11 200 000 200 000
Sum innskutt egenkapital 200 000 200 000

Opptjent egenkapital

Annen egenkapital 11 33 994 325 28 965 854
Sum opptjent egenkapital 33 994 325 28 965 854



Sum egenkapital		34 194 325	29 165 854
Sum langsiktig gjeld		0	0
Kortsiktig gjeld			
Leverandørgjeld		581 821	1 375 813
Betalbar skatt	7	1 828 869	1 931 694
Skyldige offentlige avgifter		10 699 686	10 694 314
Kortsiktig konserngjeld	3	21 738 654	9 610 029
Annen kortsiktig gjeld	5	5 159 926	5 459 670
Sum kortsiktig gjeld		40 008 956	29 071 520
Sum gjeld		40 008 956	29 071 520
SUM EGENKAPITAL OG GJELD		74 203 281	58 237 374



Organisasjonsnr: 991 729 666
ABBOTT MEDICAL NORWAY AS

NOTEOPPLYSNINGER - SELSKAP - alle poster oppgitt i hele tall

Note
1

Regnskapsprinsipper

Se vedlagt fil Abbott Medical Norway AS_Financial Statements and Annual Report_2024

Note
4

Antall årsverk i regnskapsåret
15.00

Note
4

Spesifisering av resultatregnskapet

Lønnskostnader

<u>Lønn</u>	<u>Årets</u>	<u>Fjorårets</u>
	16187009.00	16216760.00
<u>Folketrygdavgift</u>	<u>Årets</u>	<u>Fjorårets</u>
	3492422.00	3643174.00
<u>Pensjonskostnader</u>	<u>Årets</u>	<u>Fjorårets</u>
	1240831.00	1216031.00
<u>Andre ytelser</u>	<u>Årets</u>	<u>Fjorårets</u>
	-877169.00	-1834248.00

Mer om årsverk og lønn

The current CEO is employed by Abbott Scandinavia AB, Sweden. Salary or bonus has not been paid to the current CEO from Abbott Medical Norway AS during the year. There are no pension commitments to the current CEO. No personal loans or guarantees have been issued for the Managing Director, the Chairman of the Board or any other persons in management positions

Note

Ekstraordinære inntekter og kostnader

Sum Beløp



Balanseført verdi 31.12. Varige driftsmidler Immaterielle eiend.

Konsernregnskap

Morselskapet sitt navn

Forretningskontor for morselskapet

Begrunnelse for at datterselskap er utelatt fra konsolideringen

Samlet beløp - tilknyttet selskap Årets Fjorårets

Samlet beløp - foretak i samme konsern Årets Fjorårets

Samlet beløp - foretak i samme konsern Årets Fjorårets

Samlet beløp - felles kontrollert virksomhet Årets Fjorårets

Pantstillelse Beløp

Note

Beholdning av egne aksjer Antall Pålydende Andel av aksjek.

Erverv

Endringer i beholdning av aksjer i løpet av regnskapsåret

Avhendelse

Endringer i beholdning av aksjer i løpet av regnskapsåret

Samvirkeforetak

Vedtaksbestemmelser/årsmøtevedtak/forslag til vedtak om medlemskapskonti

Mer om aksjer



Skatteetaten

Vår dato
16.01.2020

Din/Deres dato
02.12.2019

Saksbehandler
Lars Waalltorp

800 80 000
Skatteetaten.no

Din/Deres referanse

Telefon
32212244

Org.nr
974761076

Vår referanse
2020/5045357

Postadresse
Postboks 9200 Grønland
0134 OSLO

ABBOTT MEDICAL NORWAY AS
Postboks 1
1330 FORNEBU

Att. David Roland Lee

Tillatelse til å utarbeide årsregnskap og årsberetning på engelsk for Abbott Medical Norway AS, org.nr. 991 729 666

Vi viser til deres brev av 2. desember 2019 der det søkes om dispensasjon fra kravet til å utarbeide årsregnskap og årsberetning på norsk for Abbott Medical Norway AS. Søknaden ble sendt til Skattedirektoratet. Skattedirektoratets myndighet til å treffe enkeltvedtak etter regnskapsloven § 3-4 tredje ledd ble delegert til skattekontoret med virkning fra 1. juni 2019.

Skattekontoret gir på bakgrunn av en konkret helhetsvurdering Abbott Medical Norway AS dispensasjon fra kravet til å utarbeide årsregnskap og årsberetning på norsk, jf. regnskapsloven § 3-4 tredje ledd. Dispensasjonen gjelder så lenge opplysningene som danner grunnlaget for vedtaket ikke endres vesentlig.

Kopi av dette brevet må sendes til Regnskapsregisteret i Brønnøysund sammen med årsregnskapet. Den regnskapspliktige må selv dokumentere ved dette brev at tillatelse er gitt.

Bakgrunn

Abbott Medical Norway AS er eid av et utenlandsk selskap og er en del av et amerikansk konsern. Konsernet driver virksomhet innen salg av medisinsk utstyr og tjenester til bedriftsmarkedet i Norge og utlandet. To av styremedlemmene i selskapet er utenlandske.

Skattekontorets vurdering

Etter regnskapsloven § 3-4 tredje ledd skal "årsregnskapet og årsberetningen [...] være på norsk. Departementet kan ved [...] enkeltvedtak bestemme at årsregnskapet og/eller årsberetningen kan være på et annet språk."

I Ot. prp. nr. 42 (1997-1998) Om lov om årsregnskap mv., er det uttalt følgende om regnskapslovens formål, jf. pkt. 1.1:

"Regjeringen har som siktemål at regnskapsloven skal bidra til informative regnskaper for ulike grupper av regnskapsbrukere. Regnskapsbrukerne er dels investorer og kreditorer som tilfører kapital til foretakene, og dels andre grupper som har interesse av å vite hvordan foretaket drives, f.eks. de ansatte og lokalsamfunnet. Informasjonen til kapitalmarkedet skal gi grunnlag for riktig prising av finansielle objekter. Riktig prisdannelse på aksjer er en forutsetning for at ressursbruken i



samfunnsøkonomien skal bli best mulig. Gode regnskaper vil også gjøre det vanskeligere for markedsdeltakere å ta ut spekulasjonsgevinster med basis i skjevt fordelt informasjon."

Det fremgår således at et av hovedformålene med regnskapsloven er å bidra til "informative regnskaper for ulike grupper av regnskapsbrukere". Regnskapsbrukere vil omfatte, jf. uttalelsen i proposisjonen, blant andre investorer, kreditorer, ansatte og lokalsamfunnet.

Det er etter skattekontorets vurdering derfor avgjørende ved vurdering av om dispensasjon fra kravet til å utarbeide årsregnskap og/eller årsberetning på norsk kan gis, at det ikke foreligger mulige brukere av regnskapsinformasjon som blir vesentlig berørt negativt ved en eventuell dispensasjon.

Det er særlig hensynet til brukerne av regnskapsinformasjon som skal vurderes ved en dispensasjonssøknad. I denne vurderingen har skattekontoret lagt særlig vekt på at selskapet er direkte eid av et utenlandsk selskap. Videre er det vektlagt at selskapet driver virksomhet i en internasjonal bransje der alle sentrale aktører behersker og benytter engelsk.

Vennligst oppgi vår referanse ved henvendelse i saken.

Med hilsen

Lars Waalorp
seniorrådgiver
Brukerdialog, brukerkontakt
Skatteetaten

Dokumentet er elektronisk godkjent og har derfor ikke håndskrevne signaturer.



Shape the future
with confidence

Statsautoriserte revisorer
Ernst & Young AS

Nygata 4
1607 Fredrikstad

Foretaksregisteret: NO 976 389 387 MVA
Tlf: +47 24 00 24 00

www.ey.no
Medlemmer av Den norske Revisorforening

To the General Meeting in Abbott Medical Norway AS

INDEPENDENT AUDITOR'S REPORT

Opinion

We have audited the financial statements of Abbott Medical Norway AS (the Company), which comprise the balance sheet as at 31 December 2024, the income statement and statement of cash flows for the year then ended and notes to the financial statements, including a summary of significant accounting policies.

In our opinion

- the financial statements comply with applicable statutory requirements, and
- the financial statements give a true and fair view of the financial position of the Company as at 31 December 2024 and its financial performance and cash flows for the year then ended in accordance with the Norwegian Accounting Act and accounting standards and practices generally accepted in Norway.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the Company in accordance with the requirements of the relevant laws and regulations in Norway and the International Ethics Standards Board for Accountants' *International Code of Ethics for Professional Accountants (including International Independence Standards)* (the IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

The Board of Directors and General Manager (management) are responsible for the information in the Board of Directors' report. Our opinion on the financial statements does not cover the information in the Board of Directors' report.

In connection with our audit of the financial statements, our responsibility is to read the information in the Board of Directors' report. The purpose is to consider if there is material inconsistency between the information in the Board of Directors' report and the financial statements or our knowledge obtained in the audit, or otherwise the information in the Board of Directors' report otherwise appears to be materially misstated. We are required to report if there is a material misstatement in the Board of Directors' report. We have nothing to report in this regard.

Based on our knowledge obtained in the audit, it is our opinion that the Board of Directors' report

- is consistent with the financial statements and
- contains the information required by applicable statutory requirements.



Shape the future
with confidence

Responsibilities of management for the financial statements

Management is responsible for the preparation of the financial statements that give a true and fair view in accordance with the Norwegian Accounting Act and accounting standards and practices generally accepted in Norway, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



**Shape the future
with confidence**

We communicate with the board of directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Fredrikstad, 27 June 2025
ERNST & YOUNG AS

The auditor's report is signed electronically

Terje Havn
State Authorised Public Accountant (Norway)

Perneo Dokumentnøkkel: Z53Y-AACTR-DUJ5Y-M1YVU-CU6ZB-QNVL



PENNEO

Signaturene i dette dokumentet er juridisk bindende. Dokument signert med "Penneo™ - sikker digital signatur". De signerende parter sin identitet er registrert, og er listet nedenfor.

"Med min signatur bekrefter jeg alle datoer og innholdet i dette dokument."

Havn, Terje

Statsautorisert revisor

Serienummer: no_bankid:9578-5994-4-464108

IP: 147.161.xxx.xxx

2025-06-27 14:23:55 UTC



Penneo Dokumentnøkkel: Z253Y-AACTR-DUU5Y-MIYU-CUGZB-QNVL

Dette dokumentet er signert digitalt via [Penneo.com](https://penneo.com). De signerte dataene er validert ved hjelp av den matematiske hashverdien av det originale dokumentet. All kryptografisk bevisføring er innebygd i denne PDF-en for fremtidig validering.

Dette dokumentet er forseglest med et kvalifisert elektronisk segl. For mer informasjon om Penneos kvalifiserte tillitstjenester, se <https://eud.penneo.com>.

Slik kan du bekrefte at dokumentet er originalt

Når du åpner dokumentet i Adobe Reader, kan du se at det er sertifisert av **Penneo A/S**. Dette beviser at innholdet i dokumentet ikke har blitt endret siden tidspunktet for signeringen. Bevis for de individuelle signatørens digitale signaturer er vedlagt dokumentet.

Du kan bekrefte de kryptografiske bevisene ved hjelp av Penneos validator, <https://penneo.com/validator>, eller andre valideringsverktøy for digitale signaturer.



Docusign Envelope ID: 2612A53E-033D-45AF-827A-A6800A2AE2CF

Abbott Medical Norway AS

Annual report 2024



Docusign Envelope ID: 2612A53E-033D-45AF-827A-A6800A2AE2CF

Abbott Medical Norway AS

CONTENTS

	Pages
Profit and loss statement	1
Balance sheet	2-3
Cash flow statement	4
Notes to financial statements	5-12
Director's report	13-14



Docusign Envelope ID: 2612A53E-033D-45AF-827A-A6800A2AE2CF

Abbott Medical Norway AS

Profit and loss statement

		2024	2023
	Note	kr	kr
Operating income			
Revenue	2	188 539 333	165 882 946
Total operating income		188 539 333	165 882 946
Operating cost			
Cost of sales	3	149 590 799	127 944 620
Payroll expenses	4	20 043 093	19 241 717
Depreciation	5	2 122 722	2 004 782
Other operating expenses	3	11 108 591	11 339 980
Total operating costs		182 865 205	160 531 099
Profit		5 674 128	5 351 847
Financial income and expenses			
Financial income	3, 6	952 605	577 280
Financial expenses	3, 6	-100 192	-231 136
Net financial items		852 413	346 144
Profit before tax		6 526 541	5 697 991
Taxes on result	7	1 498 070	1 339 328
Profit for the year		5 028 471	4 358 663



DocuSign Envelope ID: 2612A53E-033D-45AF-827A-A6800A2AE2CF

Abbott Medical Norway AS

Balance sheet

		2024-12-31	2023-12-31
	Note	kr	kr
Non-current assets			
Intangible assets			
Deferred Tax Assets		1 800 237	1 469 438
Total intangible assets		1 800 237	1 469 438
Fixed assets			
Operating equipment and other fixed assets	5	2 960 517	3 739 587
Total fixed assets		2 960 517	3 739 587
Total non-current assets		4 760 754	5 209 025
Current assets			
Inventories	3, 8	17 233 831	14 557 412
Receivables			
Accounts receivable		24 668 445	17 476 505
Other receivables	3	12 881 654	5 941 272
Total receivables		37 550 099	23 417 777
Cash and cash equivalents	9	14 658 597	15 053 160
Total current assets		69 442 527	53 028 349
Total assets		74 203 281	58 237 374
Equity and liabilities			
Share capital			
Share capital	10, 11	200 000	200 000
Total share capital		200 000	200 000
Retained equity			
Other equity	11	33 994 325	28 965 854
Total retained equity		33 994 325	28 965 854
Total equity		34 194 325	29 165 854
Liabilities			
Current liabilities			
Current liabilities to group companies	3	21 738 654	9 610 029
Trade payables		581 821	1 375 813
Tax payables	7	1 828 869	1 931 694
Unpaid public fees		10 699 686	10 694 314
Other short-term debt	3	5 159 926	5 459 670
Total current liabilities		40 008 956	29 071 520



DocuSign Envelope ID: 2612A53E-033D-45AF-827A-A6800A2AE2CF


Abbott Medical Norway AS


Balance sheet (continued)

	2024-12-31	2023-12-31
	kr	kr
Total liabilities	40 008 956	29 071 520
Total equity and liabilities	74 203 281	58 237 374

31 December 2024
, 18 June 2025

DocuSigned by:
Bradley Jay Slater
2862786D6557403
Bradley Jay Slater
Board Member

DocuSigned by:

D1AA882AC900498...
Fredrik Björnulfson
Chairman of the Board

DocuSigned by:

0FD3A540BC28496...
Andreas Almroth
Managing Director



Docusign Envelope ID: 2612A53E-033D-45AF-827A-A6800A2AE2CF

Abbott Medical Norway AS

Cash flow statement

	2024-12-31	2023-12-31
	kr	kr
<i>Cash flow from operating activities</i>		
Result before tax	6 526 541	5 697 991
Income Tax Paid	-1 931 694	-1 410 728
Gain/loss on Disposal of Fixed Assets	1 991 382	3 242 824
Depreciation on Fixed Assets and Intangible Assets	2 122 722	2 004 782
Change in Inventory	-2 676 419	1 071 507
Change in Receivables	-14 132 321	1 608 057
Change in Trade Accounts payable	-793 992	255 820
Change in Liabilities to Group Companies	12 128 625	-4 652 870
Change in Public Duties Payable	5 372	1 814 358
Change in Other Accrued Entries	-299 745	-1 572 347
Total cash flow from operating activities	2 940 471	8 059 394
<i>Cash flow from investing activities</i>		
Investments in Fixed Assets	-3 335 034	-5 028 839
Total cash flow from investing activities	-3 335 034	-5 028 839
Net cash flow for the year	-394 563	3 030 555
Cash and cash equivalents at 01.01	15 053 160	12 022 605
Cash and cash equivalents at 31.12	14 658 597	15 053 160



DocuSign Envelope ID: 2612A53E-033D-45AF-827A-A6800A2AE2CF

Abbott Medical Norway AS

Notes to financial statements

Company information and ownership structure

Abbott Medical Norway AS office is located at Rolfsbuktheien 4C, 1364 Fornebu.

Abbott Medical Norway AS is a wholly owned subsidiary of Abbott Norge AS, Rolfsbuktheien 4C, 1364 Fornebu.

The group parent company is Abbott laboratories with residence in Illinois, USA.

The reporting currency is NOK.

Note 1 - Accounting policies

The annual report is prepared according to the Norwegian Accounting Act 1998 and generally accepted accounting principles.

Balance sheet classification

Current assets and current liabilities include items due for payment within one year after the balance sheet date of acquisition, as well as items related to the product cycle. Other items are classified as fixed assets / long-term liabilities.

Current assets are valued at the lower of acquisition cost and fair value. Short-term debt is assessed to face value.

Fixed assets are valued at acquisition cost. Long-term fixed assets with a limited economic life are amortised according to a reasonable depreciation plan. Fixed assets are written down to fair value if impairment is not expected to be temporary. Long-term liabilities with the exception of other provisions are capitalised at nominal amount.

Current receivables

Trade receivables and other receivables are entered in the balance sheet at nominal value after deduction of provisions for expected losses. Provisions for losses are made on the basis of individual assessments of the individual receivables. In addition, for other accounts receivable, an unspecified provision is made to cover expected losses.

Inventory

Inventories are valued at the lower cost or market value. Write-downs are carried out for foreseeable obsolescence.

Cash, Cash Equivalents and Investments

Cash and Cash Equivalents consist of cash and time deposits with an original maturity date of three months or less.

Warranties and Performed Service

Income related to future warranty and service are not recorded as earned income but instead booked as Deferred Income under Other Accounts Payables. The deferred income is booked as linear income over the warranty and service period.



DocuSign Envelope ID: 2612A53E-033D-45AF-827A-A6800A2AE2CF

Abbott Medical Norway AS

Notes to financial statements (continued)

Note 1 - Accounting policies (continued)

Property, plant and equipment

Property, plant and equipment is capitalized and depreciated over its estimated useful economic life. Direct maintenance costs are expensed as incurred, whereas improvements and upgrading are assigned to the acquisition cost and depreciation along with the asset.

Intangible assets

Intangible Assets acquired through the acquisition of a business, are booked at acquisition value providing the justification for booking the balance exists. Intangible Assets with limited useful life are amortized according to plan. Intangible Assets are written down if the economic expectations do not justify the value booked.

Sales revenue

Sales revenues are recognized at the time of delivery. Revenue from services is recognized at execution. The share of sales revenue associated with future services is recorded in the balance sheet as deferred sales revenue, and recognized at the time of execution.

Expenses

Expenses and related income are in general booked in the same period. In those circumstances where there are no direct link between expenses and income, an allocation is estimated. Other exceptions are reported where relevant.

Pensions – Defined Contribution scheme

The company has defined-contribution plan. The employer makes a contribution to the employee's pension savings. The future pension depends on the size of the contribution and the return on the pension assets. In defined-contribution pensions the cost to the company is equal to the contributions for the year, and the company's only commitment is to make an annual contribution. Thus, no liability is recorded in the balance sheet.

Currency

Cash items, receivables and liabilities in foreign currency are assessed at the exchange rate at the end of the financial year. The effect of changes is included in the income statement.

Taxes

Tax expense in the profit and loss account, is comprised of both tax payable for the accounting period and changes in deferred tax. Deferred tax is calculated at 22 percent on the basis of existing temporary differences between accounting profit. Taxable profit is netted together with tax-deductible deficits at year-end. Positive and negative temporary differences are balanced out within the same period. Deferred tax assets are recorded in the balance sheet to the extent that it is likely that this will be utilized.

Cash flow Statement

The cash flow statement has been prepared according to the indirect method. Cash and cash equivalents include cash, bank deposits and other short-term, highly liquid investments with maturities of three months or less.



DocuSign Envelope ID: 2612A53E-033D-45AF-827A-A6800A2AE2CF

Abbott Medical Norway AS

Notes to financial statements (continued)

Note 2 - Sales revenue

	2024	2023
	kr	kr
Area of activity:		
Medical devices	188 539 333	165 882 946

All sales are made to customers in the Norwegian market.

Note 3 - Transactions with enterprises in the same group and affiliated companies

	2024	2023
	kr	kr
Transactions		
Cost of goods *	149 810 445	128 995 489
Expenses paid for centralized services **	840 000	840 000
Other income *	572 154	249 242
Other expenses *	236 759	580 168
Total controlled operational transactions	151 459 358	130 664 899
Purchase of tangible fixed assets *	3 335 034	0
Total controlled transactions regarding fixed assets	3 335 034	0
Interest on receivables in cash pool arrangements ****	285 976	179 094
Interest on payables in cash pool arrangements ****	48 748	64 930
Total controlled financial transactions	334 724	244 024
	Group Companies	
	2024	2023
	kr	kr
Payables in cash pool arrangements ****	-2 162	-8 168
Receivables in cash pool arrangements ****	12 638 323	4 920 255
Current liabilities *	-21 736 492	-9 601 861
Total	-9 100 331	-4 689 774

* Items relates to transactions with SJM Coordination Center BVBA, Belgium and Abbott Vascular, The Netherlands.

** Items related to transactions with Abbott Norge AS, Norway

*** Items related to transactions with SJM Coordination Center BVBA, Belgium

**** Items related to transactions with Abbott Luxembourg Finance Sarl, Luxembourg



Docusign Envelope ID: 2612A53E-033D-45AF-827A-A6800A2AE2CF

Abbott Medical Norway AS

Notes to financial statements (continued)

Note 4 - Wages, number of employees, remuneration etc

	2024	2023
	kr	kr
Wage costs:		
Salaries	16 187 009	16 216 760
Payroll tax	3 492 422	3 643 174
Pension cost	1 240 831	1 216 031
Other payments	-877 169	-1 834 248
Total	20 043 093	19 241 717

Average number of employees was 15 in 2024 and 16 in 2023.

2024

The current CEO is employed by Abbott Scandinavia AB, Sweden. Salary or bonus has not been paid to the current CEO from Abbott Medical Norway AS during the year. There are no pension commitments to the current CEO.

No personal loans or guarantees have been issued for the Managing Director, the Chairman of the Board or any other persons in management positions

Expensed fees to external auditors are as follows:

	2024	2023
	kr	kr
Statutory auditing	116 765	112 816



DocuSign Envelope ID: 2612A53E-033D-45AF-827A-A6800A2AE2CF

Abbott Medical Norway AS

Notes to financial statements (continued)

Note 5 - Fixed assets

	Instruments kr	Furniture and Office Equipment kr	Total kr
2024			
Acquisition costs at the start of the year	7 935 439	291 254	8 226 693
Purchased Tangibles	3 335 034	0	3 335 034
Disposal	-2 906 072	0	-2 906 072
Acquisition costs at the end of the year	8 364 401	291 254	8 655 655
Accumulated depreciation	-5 496 518	-198 620	-5 695 138
Net Book Value 31.12.24	2 867 883	92 634	2 960 517
Depreciation for the year	2 034 645	88 077	2 122 722

Ordinary depreciation is provided on a straight-line basis for the company at the following rates based on the expected economic lives:

	IT equipment	Instruments
Lifetime	3	3

The Company's office space 5 year rental agreement at Rolfsbuktheien 4C expires on the 31st October 2029. The remaining leasing period for cars is up to 4,5 years.

	2024 kr	2023 kr
Yearly rental costs		
Office rent	840 000	840 000
Car leasing	1 031 510	1 206 056
	1 871 510	2 046 056



Docusign Envelope ID: 2612A53E-033D-45AF-827A-A6800A2AE2CF

Abbott Medical Norway AS

Notes to financial statements (continued)

Note 6 - Items consisting of consolidated amounts

Specification of financial income

Interest Income from Companies in the Group
Interest income
Foreign Exchange Gain
Total financial income

2024	2023
kr	kr
285 976	179 094
664 566	369 579
2 062	28 607
<u>952 604</u>	<u>577 280</u>

Specification of financial costs

Interest expense to Companies in the Group
Interest Expense
Financial Expense, other
Foreign Exchange Loss
Total financial expenses

2024	2023
kr	kr
48 748	64 930
15 895	2 159
25 822	22 733
9 727	141 314
<u>100 192</u>	<u>231 136</u>



DocuSign Envelope ID: 2612A53E-033D-45AF-827A-A6800A2AE2CF

Abbott Medical Norway AS

Notes to financial statements (continued)

Note 7 - Tax expenses

Tax expense for the year comprises of:

Income tax expense:

Current taxes
Impact of changes in tax rate
Impact of changes in deferred tax base
Total tax expense

2024	2023
kr	kr
1 828 869	1 931 694
0	0
-330 799	-592 366
1 498 070	1 339 328

Current taxes
Current tax liability
Total current taxes

2024	2023
kr	kr
1 828 869	1 931 694
0	0
1 828 869	1 931 694

Reconciliation of tax expense

Profit before tax
Expected Income Tax, Statutory Tax Rate
Tax Impact of the following items:
Other permanent differences
Income tax expense

2024	2023
kr	kr
6 526 541	5 697 991
1 435 839	1 253 558
62 231	85 770
1 498 070	1 339 328

Effective tax rate

2024	2023
22,95	23,51

Specification of tax impact of temporary differences:

Fixed assets
Goods
Pension assets (obligations)
Total

2024	2023
kr	kr
-8 018 825	-6 670 057
-164 069	-48 697
0	39 491
-8 182 894	-6 679 263

Deferred tax assets are recorded based on future revenue. Deferred taxes are based on temporary differences.



Docusign Envelope ID: 2612A53E-033D-45AF-827A-A6800A2AE2CF

Abbott Medical Norway AS

Notes to financial statements (continued)

Note 8 - Inventory

	2024	2023
	kr	kr
Provision for obsolete items	-164 069	-48 697
Finished goods	17 397 900	14 606 109
Total	17 233 831	14 557 412

Note 9 - Bank Deposits

A restricted bank deposit to cover the tax obligations of the employees represented NOK 871 641 as of 31.12.24.

Note 10 - Share capital and shareholder information

	Number of shares	Nominal value kr	Book value kr
2024			
The share capital consists of:			
A-shares	100	2 000,00	200 000
The shares are wholly owned by Abbott Norge AS, Norway			

Note 11 - Owners Equity

	Share capital kr	Other equity kr	Total kr
2024			
Equity at the start of the year	200 000	28 965 854	29 165 854
Net result of the year	0	5 028 471	5 028 471
Equity 31.12	200 000	33 994 325	34 194 325

Note 12 - Events after the balance sheet date

No events materially affecting the Company have occurred after the balance sheet date.



DocuSign Envelope ID: 2612A53E-033D-45AF-827A-A6800A2AE2CF

Abbott Medical Norway AS

Director's report

Abbott Medical Norway AS operates in five business areas:

Cardiac Rhythm Management: A healthy heart is essential to good health. That's why we're committed to advancing treatments for people with cardiovascular disease. Our breakthrough medical technologies help restore people's health so they can get back to living their best lives, faster. We focus on innovative technologies that can improve the way doctors treat people with heart arrhythmias, or irregular heartbeats. Our cardiac rhythm management devices keep the heart beating at a healthy pace with pacemakers, implantable cardiac defibrillators and implantable cardiac monitors, all designed to get people's hearts working better sooner.

Electrophysiology and Heart Failure: Our cardiac arrhythmia devices keep the heart beating at a healthy pace with diagnostic and ablation catheters, mapping and visualization systems. Solutions for treating heart failure with devices to resynchronize heart beats, a pulmonary artery pressure monitoring system, and left ventricle assist devices mean we have many ways to get people's hearts working better sooner.

Neuromodulation: We offer specialized devices for people suffering from chronic pain and movement disorders through solutions that deliver stimulation to the spinal cord, dorsal root ganglion and the brain.

Structural Heart: Devices for treatment of structural heart disease.

Vascular: Abbott Vascular is the world's leader in drug-eluting stents. Abbott Vascular has an industry-leading pipeline and a comprehensive portfolio of market-leading products for cardiac and vascular care, including products for coronary artery disease, vessel closure and endovascular disease. The company's activities consisted mainly of marketing, sales and distribution of products and services to the Norwegian health sector.

The company's activities consisted mainly of marketing, sales and distribution of products and services to the Norwegian health sector.

The company's office is located at IT Fornebu in Bærum municipality.

The working environment has been satisfactory throughout the year. Absence due to sickness has been 174 working days for 2024, which is 4.6% of total working days. There have been no personal injuries or accidents during 2024. The company works systematically and continuously to improve the working environment. The company's business does not result in pollution or emissions that can be harmful for the environment.

The Board of Directors confirms that the financial statements give a true and fair view of Abbott Medical Norway AS assets and liabilities, financial status and profitability. Total assets were NOK 74.2 million as of 31.12.24. Approximately 51% of the assets consist of short-term receivables. Compared to 2023 year-end, total assets increased by approximately 27%, which was mainly due to the increase in short-term receivables. Total equity at year-end was NOK 34.2 million, compared to NOK 29.2 million as of year-end 2023. The change in equity is due to the profit for the year. The liability of the company consists primarily of short-term debt. Net change in the cash flows compared to 2023 is mainly influenced by the 2024 change in Receivables.

The overall sales of Abbott Medical Norway AS increased by 13.7%, due to growth by several divisions, especially Structural Heart and Electrophysiology.



DocuSign Envelope ID: 2612A53E-033D-45AF-827A-A6800A2AE2CF

Abbott Medical Norway AS

Director's report

The credit risk is monitored by continuous credit appraisal of Abbott's customers. Historically, there has been almost no loss due to a stable customer portfolio. The company's cash flow exposure is considered low. Access to short term inter-company loans hedges any cash flow exposure. The company considers the market exposure in general to be low. Most of the products are sold to public hospitals under contractual tender agreements. These contracts typically have a duration of two years before being re-negotiated under the public tender process.

Abbott Medical Norway AS is a fully owned subsidiary, part of the Abbott Group and also their global insurance program. No local insurance policy for the board of directors of Abbott Medical Norway AS have been taken.

As a global healthcare leader, diversity is not just a moral virtue, it is a business necessity. We believe advancing diversity is critical. Diversity fuels creativity that drives innovation.

Innovation produces life-changing technology that allows Abbott to serve its purpose - helping people live healthier, fuller lives.

As required by Norway's Equality and Anti-discrimination Act, Abbott examined risks of gender discrimination through assessment of pay, benefit programs, policies, and routines.


For 2024, Abbott has achieved a representative gender balance of employees. 50% were women and 50% were men. Abbott deploys no different policies for sub-groups, and no risks of discrimination were identified during the assessment. To continue this state, we will keep reinforcing our focus on avoiding discrimination, of all kind, in our policies, programs, and practices to make sure we deliver on our commitments to our employees and to the communities where they live and work.


Abbott Medical Norway AS is required to do Transparency Act reporting and the report has been published on <https://www.no.abbott>.

The financial statements have been prepared under the assumption that the business will continue to operate as a going concern.

Abbott Medical Norway AS profit for the year is NOK 5,028,471. The Board of Directors suggests transferring the profit to retained earnings.

DocuSigned by:
Bradley Jay Slater
2862768D6557403
Bradley Jay Slater
Board Member

DocuSigned by:

D:AA882ACC90498
Fredrik Björnulfson
Chairman of the Board

DocuSigned by:

9F32A640BC28496
Andreas Almroth
Managing Director